Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02750865 · ClinicalTrials.gov registry record · NA

Conversational Agents to Improve Quality of Life in Palliative Care

A NA study of Palliative Care, sponsored by Boston Medical Center.

Completed
Registry status
NA
Development phase
367
Enrollment target
1
Study location

NCT02750865: Completed NA study of Palliative Care, sponsored by Boston Medical Center.

NCT02750865 is a NA study of Palliative Care that has completed, run by Boston Medical Center. The registered enrollment target is 367 participants, below the 1,396-participant average among 18 other Palliative Care trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02750865, a NA study of Palliative Care, has completed, sponsored by Boston Medical Center.

COMPLETED
Registry status
NA
Development phase
367 participants
Enrollment target
1
Study location

Study Summary

In this study the investigators will advance research on the development of easy to use technologies to empower patients. This is a scalable approach that has a significant potential to reduce suffering for palliative care patients and their caregivers. The investigators will adapt existing tested empathic conversational agents (ECA) for home-based cancer care management and inpatient bedside counseling to provide the following functions: 1. medication counseling; 2. physical activity promotion; 3. symptom management and continual screening for adverse events; and 4. alleviation of stress and anxiety 5. spiritual needs assessment; and 6. advanced care planning. Data from the system will be monitored by a health professional, who communicates with members of the patient's care team. In this project, this activity will include facilitating referral for palliative care services. The investigators will conduct pilot studies both at Boston Medical Center and at Northeastern University that will test system usability (Northeastern University and BMC) as well as interview burden (BMC only). The investigators will conduct a Randomized Control Trial (RCT) to evaluate the agent technology, comparing usual care (UC) versus usual care plus the agent (UC+ECA) for patients 21 or older, with a life expectancy of \< 1 year, from outpatient clinics at Boston Medical Center (BMC). Each subject will be enrolled along with a caregiver surrogate subject. In addition to baseline data collection, there will be monthly phone surveys for six months; intervention subjects will use the system for a six-month period of time. In addition, the investigators will conduct a randomized trial within the intervention group to compare subjects getting functions 1-4 (above) versus subjects getting the augmented intervention with all six functions. The intervention will include a nurse management interface to monitor clinical alerts generated by the system to stimulate interventions by the clinical

Primary Outcome

QOL will be assessed using QLQ-C15-PAL, a 15-scale-item instrument designed to assess the quality of life of participants.

Conditions Studied

Interventions

  • BEHAVIORAL Embodied Conversational Agent (ECA)

Study Locations (1)

Massachusetts

  • Boston Medical Center - Boston

Trial Details

FieldValue
Enrollment Target 367 participants
Start Date 2017-08-02
Est. Completion 2022-10-24
Phase NA
Boston Medical Center

253 total trials

What the finished NCT02750865 record still lists

NCT02750865 is an interventional study that assigns participants to a tested intervention. The registered 367 participants enrollment target is mid-sized for trials with a published cap, below the 1,396-participant average among 18 other Palliative Care trials with a reported enrollment target (74% lower).

The record links to 1 condition, with Palliative Care appearing as the primary indexed condition, and to 1 intervention - of which Embodied Conversational Agent (ECA) is the first listed.

NCT02750865 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02750865 about?

NCT02750865 is a clinical study titled "Conversational Agents to Improve Quality of Life in Palliative Care". In this study the investigators will advance research on the development of easy to use technologies to empower patients. This is a scalable approach that has a significant potential to reduce suffering for palliative care patients and their caregivers. The investigators will adapt existing tested e...

What is the current status of trial NCT02750865?

This trial is currently completed. It is a NA study. The enrollment target is 367 participants. The study started on 2017-08-02. Estimated completion is 2022-10-24.

What conditions does trial NCT02750865 study?

This clinical trial studies the following conditions: Palliative Care.

What interventions are being tested in trial NCT02750865?

The interventions under investigation include: Embodied Conversational Agent (ECA) (BEHAVIORAL).

Who is sponsoring clinical trial NCT02750865?

This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02750865 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Palliative Care

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02750865's enrollment target sits among peer trials

367 5th of 18 higher than 14 of 18 other Palliative Care trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Palliative Care trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04675476 · 368 participants · NA

    A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening

  • NCT05215353 · 368 participants · Phase 4

    A Study Comparing Music Therapy and Cognitive Behavioral Therapy for Anxiety in Cancer Survivors

  • NCT06182397 · 368 participants · NA

    Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease

  • NCT06629610 · 368 participants · NA

    Diet and Active Lifestyle - Yuuyaraq (The Yup'ik Way of Life)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02750865, the US trial registry maintained by the National Library of Medicine. NCT02750865 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.